

Heinz-Josef Lenz

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/8224219/heinz-josef-lenz-publications-by-year.pdf>

Version: 2024-04-23

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

225
papers

17,389
citations

58
h-index

130
g-index

236
ext. papers

21,080
ext. citations

8.1
avg. IF

6.52
L-index

#	Paper	IF	Citations
225	Efficacy of anti-epidermal growth factor receptor agents in patients with RAS wild-type metastatic colorectal cancer ≥ 70 years.. <i>European Journal of Cancer</i> , 2022 , 163, 1-15	7.5	0
224	Molecular characteristics and clinical outcomes of patients with Neurofibromin 1-altered metastatic colorectal cancer. <i>Oncogene</i> , 2021 ,	9.2	2
223	Role of enterocyte-specific gene polymorphisms in response to adjuvant treatment for stage III colorectal cancer. <i>Pharmacogenetics and Genomics</i> , 2021 , 31, 10-16	1.9	1
222	Molecular differences between lymph nodes and distant metastases compared with primaries in colorectal cancer patients. <i>Npj Precision Oncology</i> , 2021 , 5, 95	9.8	1
221	First-Line Nivolumab Plus Low-Dose Ipilimumab for Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: The Phase II CheckMate 142 Study. <i>Journal of Clinical Oncology</i> , 2021 , JCO2101015	2.2	29
220	Reprogramming CBX8-PRC1 function with a positive allosteric modulator. <i>Cell Chemical Biology</i> , 2021 ,	8.2	3
219	RNA-Binding Protein Polymorphisms as Novel Biomarkers to Predict Outcomes of Metastatic Colorectal Cancer: A Meta-analysis from TRIBE, FIRE-3, and MAVERICC. <i>Molecular Cancer Therapeutics</i> , 2021 , 20, 1153-1160	6.1	0
218	BRAF V600E Mutation in First-Line Metastatic Colorectal Cancer: An Analysis of Individual Patient Data From the ARCAD Database. <i>Journal of the National Cancer Institute</i> , 2021 , 113, 1386-1395	9.7	3
217	The Landscape of Alterations in DNA Damage Response Pathways in Colorectal Cancer. <i>Clinical Cancer Research</i> , 2021 , 27, 3234-3242	12.9	5
216	Clocking cancer: the circadian clock as a target in cancer therapy. <i>Oncogene</i> , 2021 , 40, 3187-3200	9.2	7
215	Molecular Determinants of Gastrointestinal Cancers. <i>Advances in Oncology</i> , 2021 , 1, 311-325		
214	Random survival forests identify pathways with polymorphisms predictive of survival in KRAS mutant and KRAS wild-type metastatic colorectal cancer patients. <i>Scientific Reports</i> , 2021 , 11, 12191	4.9	0
213	Germ line polymorphisms of genes involved in pluripotency transcription factors predict efficacy of cetuximab in metastatic colorectal cancer. <i>European Journal of Cancer</i> , 2021 , 150, 133-142	7.5	1
212	Prognostic and Predictive Impact of Primary Tumor Sidedness for Previously Untreated Advanced Colorectal Cancer. <i>Journal of the National Cancer Institute</i> , 2021 ,	9.7	2
211	Large-scale analysis of KMT2 mutations defines a distinctive molecular subset with treatment implication in gastric cancer. <i>Oncogene</i> , 2021 , 40, 4894-4905	9.2	2
210	IGF-Binding Proteins, Adiponectin, and Survival in Metastatic Colorectal Cancer: Results From CALGB (Alliance)/SWOG 80405. <i>JNCI Cancer Spectrum</i> , 2021 , 5, pkaa074	4.6	2
209	Clinical Validation of a Machine-learning-derived Signature Predictive of Outcomes from First-line Oxaliplatin-based Chemotherapy in Advanced Colorectal Cancer. <i>Clinical Cancer Research</i> , 2021 , 27, 1174-1183	12.9	7

208	Human-specific polymorphic pseudogenization of protects against advanced cancer progression. <i>FASEB BioAdvances</i> , 2021 , 3, 69-82	2.8	6
207	Association of Consensus Molecular Subtypes and Molecular Markers With Clinical Outcomes in Patients With Metastatic Colorectal Cancer: Biomarker Analyses From LUME-Colon 1. <i>Clinical Colorectal Cancer</i> , 2021 , 20, 84-95.e8	3.8	8
206	Genomic Analysis of Germline Variation Associated with Survival of Patients with Colorectal Cancer Treated with Chemotherapy Plus Biologics in CALGB/SWOG 80405 (Alliance). <i>Clinical Cancer Research</i> , 2021 , 27, 267-275	12.9	2
205	Phase I Assessment of Safety and Therapeutic Activity of BAY1436032 in Patients with IDH1-Mutant Solid Tumors. <i>Clinical Cancer Research</i> , 2021 , 27, 2723-2733	12.9	12
204	Clinical significance of enterocyte-specific gene polymorphisms as candidate markers of oxaliplatin-based treatment for metastatic colorectal cancer. <i>Pharmacogenomics Journal</i> , 2021 , 21, 285-295	3.5	0
203	Distinct genomic landscapes of gastroesophageal adenocarcinoma depending on PD-L1 expression identify mutations in RAS-MAPK pathway and TP53 as potential predictors of immunotherapy efficacy. <i>Annals of Oncology</i> , 2021 , 32, 906-916	10.3	0
202	Homologous Recombination Deficiency Alterations in Colorectal Cancer: Clinical, Molecular, and Prognostic Implications. <i>Journal of the National Cancer Institute</i> , 2021 ,	9.7	4
201	Potential Molecular Cross Talk Among CCR5 Pathway Predicts Regorafenib Responsiveness in Metastatic Colorectal Cancer Patients. <i>Cancer Genomics and Proteomics</i> , 2021 , 18, 317-324	3.3	0
200	Overcoming resistance to anti-PD1 and anti-PD-L1 treatment in gastrointestinal malignancies 2020 , 8,		15
199	-Mutated Colorectal Cancer Is Characterized by a Distinct Genetic Phenotype. <i>Cancers</i> , 2020 , 12,	6.6	7
198	Combination of variations in inflammation- and endoplasmic reticulum-associated genes as putative biomarker for bevacizumab response in KRAS wild-type colorectal cancer. <i>Scientific Reports</i> , 2020 , 10, 9778	4.9	1
197	Immune phenotype and histopathological growth pattern in patients with colorectal liver metastases. <i>British Journal of Cancer</i> , 2020 , 122, 1518-1524	8.7	17
196	ctDNA applications and integration in colorectal cancer: an NCI Colon and Rectal-Anal Task Forces whitepaper. <i>Nature Reviews Clinical Oncology</i> , 2020 , 17, 757-770	19.4	82
195	Single Nucleotide Polymorphisms in MiRNA Binding Sites of Nucleotide Excision Repair-Related Genes Predict Clinical Benefit of Oxaliplatin in FOLFOXIRI Plus Bevacizumab: Analysis of the TRIBE Trial. <i>Cancers</i> , 2020 , 12,	6.6	2
194	Epidermal growth factor receptor mRNA expression: A potential molecular escape mechanism from regorafenib. <i>Cancer Science</i> , 2020 , 111, 441-450	6.9	5
193	A polymorphism within the R-spondin 2 gene predicts outcome in metastatic colorectal cancer patients treated with FOLFIRI/bevacizumab: data from FIRE-3 and TRIBE trials. <i>European Journal of Cancer</i> , 2020 , 131, 89-97	7.5	3
192	Body Mass Index and Weight Loss in Metastatic Colorectal Cancer in CALGB (Alliance)/SWOG 80405. <i>JNCI Cancer Spectrum</i> , 2020 , 4, pkaa024	4.6	4
191	A polymorphism in the cachexia-associated gene INHBA predicts efficacy of regorafenib in patients with refractory metastatic colorectal cancer. <i>PLoS ONE</i> , 2020 , 15, e0239439	3.7	3

190	Molecular Characterization of Appendiceal Goblet Cell Carcinoid. <i>Molecular Cancer Therapeutics</i> , 2020 , 19, 2634-2640	6.1	4
189	Phase II Trial of Neoadjuvant Bevacizumab with Modified FOLFOX7 in Patients with Stage II and III Rectal Cancer. <i>Oncologist</i> , 2020 , 25, e1879-e1885	5.7	0
188	Immunogenic cell death pathway polymorphisms for predicting oxaliplatin efficacy in metastatic colorectal cancer 2020 , 8,		4
187	The structure-function relationship of oncogenic LMTK3. <i>Science Advances</i> , 2020 , 6,	14.3	7
186	Comprehensive Genomic Profiling of Gastroenteropancreatic Neuroendocrine Neoplasms (GEP-NENs). <i>Clinical Cancer Research</i> , 2020 , 26, 5943-5951	12.9	17
185	Diabetes and Clinical Outcome in Patients With Metastatic Colorectal Cancer: CALGB 80405 (Alliance). <i>JNCI Cancer Spectrum</i> , 2020 , 4, pkz078	4.6	12
184	A polymorphism in the cachexia-associated gene INHBA predicts efficacy of regorafenib in patients with refractory metastatic colorectal cancer 2020 , 15, e0239439		
183	A polymorphism in the cachexia-associated gene INHBA predicts efficacy of regorafenib in patients with refractory metastatic colorectal cancer 2020 , 15, e0239439		
182	A polymorphism in the cachexia-associated gene INHBA predicts efficacy of regorafenib in patients with refractory metastatic colorectal cancer 2020 , 15, e0239439		
181	A polymorphism in the cachexia-associated gene INHBA predicts efficacy of regorafenib in patients with refractory metastatic colorectal cancer 2020 , 15, e0239439		
180	Health-related Quality of Life in the Phase III LUME-Colon 1 Study: Comparison and Interpretation of Results From EORTC QLQ-C30 Analyses. <i>Clinical Colorectal Cancer</i> , 2019 , 18, 269-279.e5	3.8	3
179	Molecular Profiling of Appendiceal Adenocarcinoma and Comparison with Right-sided and Left-sided Colorectal Cancer. <i>Clinical Cancer Research</i> , 2019 , 25, 3096-3103	12.9	30
178	Quantitative evidence for early metastatic seeding in colorectal cancer. <i>Nature Genetics</i> , 2019 , 51, 1113-1122	16.2	164
177	The current state of molecular testing in the treatment of patients with solid tumors, 2019. <i>Ca-A Cancer Journal for Clinicians</i> , 2019 , 69, 305-343	220.7	86
176	Impact of Consensus Molecular Subtype on Survival in Patients With Metastatic Colorectal Cancer: Results From CALGB/SWOG 80405 (Alliance). <i>Journal of Clinical Oncology</i> , 2019 , 37, 1876-1885	2.2	98
175	The safety and efficacy of trifluridine-tipiracil for metastatic colorectal cancer: A pharmacy perspective. <i>American Journal of Health-System Pharmacy</i> , 2019 , 76, 339-348	2.2	5
174	Impact of polymorphisms within genes involved in regulating DNA methylation in patients with metastatic colorectal cancer enrolled in three independent, randomised, open-label clinical trials: a meta-analysis from TRIBE, MAVERICC and FIRE-3. <i>European Journal of Cancer</i> , 2019 , 111, 138-147	7.5	3
173	A phase 1b study evaluating the safety and pharmacokinetics of regorafenib in combination with cetuximab in patients with advanced solid tumors. <i>International Journal of Cancer</i> , 2019 , 145, 2450-2458	7.5	5

172	Mutational Analysis of Patients With Colorectal Cancer in CALGB/SWOG 80405 Identifies New Roles of Microsatellite Instability and Tumor Mutational Burden for Patient Outcome. <i>Journal of Clinical Oncology</i> , 2019 , 37, 1217-1227	2.2	140
171	Novel Common Genetic Susceptibility Loci for Colorectal Cancer. <i>Journal of the National Cancer Institute</i> , 2019 , 111, 146-157	9.7	67
170	Impact of Patient Age on Molecular Alterations of Left-Sided Colorectal Tumors. <i>Oncologist</i> , 2019 , 24, 319-326	5.7	19
169	Aryl hydrocarbon receptor nuclear translocator-like (ARNTL/BMAL1) is associated with bevacizumab resistance in colorectal cancer via regulation of vascular endothelial growth factor A. <i>EBioMedicine</i> , 2019 , 45, 139-154	8.8	19
168	Regorafenib dose-optimisation in patients with refractory metastatic colorectal cancer (ReDOS): a randomised, multicentre, open-label, phase 2 study. <i>Lancet Oncology, The</i> , 2019 , 20, 1070-1082	21.7	101
167	Molecular insight of regorafenib treatment for colorectal cancer. <i>Cancer Treatment Reviews</i> , 2019 , 81, 101912	14.4	44
166	Nivolumab (NIVO) + low-dose ipilimumab (IPI) in previously treated patients (pts) with microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): Long-term follow-up.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 635-635	2.2	22
165	MAVERICC, a Randomized, Biomarker-stratified, Phase II Study of mFOLFOX6-Bevacizumab versus FOLFIRI-Bevacizumab as First-line Chemotherapy in Metastatic Colorectal Cancer. <i>Clinical Cancer Research</i> , 2019 , 25, 2988-2995	12.9	31
164	Role of CCL5 and CCR5 gene polymorphisms in epidermal growth factor receptor signalling blockade in metastatic colorectal cancer: analysis of the FIRE-3 trial. <i>European Journal of Cancer</i> , 2019 , 107, 100-114	7.5	5
163	Genetic variants in CCL5 and CCR5 genes and serum VEGF-A levels predict efficacy of bevacizumab in metastatic colorectal cancer patients. <i>International Journal of Cancer</i> , 2019 , 144, 2567-2577	7.5	2
162	Safety and Tolerability of c-MET Inhibitors in Cancer. <i>Drug Safety</i> , 2019 , 42, 211-233	5.1	40
161	Landscape of Tumor Mutation Load, Mismatch Repair Deficiency, and PD-L1 Expression in a Large Patient Cohort of Gastrointestinal Cancers. <i>Molecular Cancer Research</i> , 2018 , 16, 805-812	6.6	114
160	Prognostic Value of ACVRL1 Expression in Metastatic Colorectal Cancer Patients Receiving First-line Chemotherapy With Bevacizumab: Results From the Triplet Plus Bevacizumab (TRIBE) Study. <i>Clinical Colorectal Cancer</i> , 2018 , 17, e471-e488	3.8	4
159	Outlooks on Epstein-Barr virus associated gastric cancer. <i>Cancer Treatment Reviews</i> , 2018 , 66, 15-22	14.4	74
158	The role of tumor angiogenesis as a therapeutic target in colorectal cancer. <i>Expert Review of Anticancer Therapy</i> , 2018 , 18, 251-266	3.5	29
157	The subgroups of the phase III RECURSE trial of trifluridine/tipiracil (TAS-102) versus placebo with best supportive care in patients with metastatic colorectal cancer. <i>European Journal of Cancer</i> , 2018 , 90, 63-72	7.5	48
156	Gene Polymorphisms in the CCL5/CCR5 Pathway as a Genetic Biomarker for Outcome and Hand-Foot Skin Reaction in Metastatic Colorectal Cancer Patients Treated With Regorafenib. <i>Clinical Colorectal Cancer</i> , 2018 , 17, e395-e414	3.8	16
155	A phase 1 dose-escalation study of veliparib with bimonthly FOLFIRI in patients with advanced solid tumours. <i>British Journal of Cancer</i> , 2018 , 118, 938-946	8.7	19

154	Biomarker-driven and molecular targeted therapies for colorectal cancers. <i>Seminars in Oncology</i> , 2018 , 45, 124-132	5.5	7
153	Potential role of PIN1 genotypes in predicting benefit from oxaliplatin-based and irinotecan-based treatment in patients with metastatic colorectal cancer. <i>Pharmacogenomics Journal</i> , 2018 , 18, 623-632	3.5	4
152	Molecular biomarkers in gastro-esophageal cancer: recent developments, current trends and future directions. <i>Cancer Cell International</i> , 2018 , 18, 99	6.4	34
151	Differentiation Therapy Targeting the β Catenin/CBP Interaction in Pancreatic Cancer. <i>Cancers</i> , 2018 , 10,	6.6	27
150	Comparative Molecular Analyses of Esophageal Squamous Cell Carcinoma, Esophageal Adenocarcinoma, and Gastric Adenocarcinoma. <i>Oncologist</i> , 2018 , 23, 1319-1327	5.7	61
149	NOS2 polymorphisms in prediction of benefit from first-line chemotherapy in metastatic colorectal cancer patients. <i>PLoS ONE</i> , 2018 , 13, e0193640	3.7	3
148	Association Between Height and Clinical Outcome in Metastatic Colorectal Cancer Patients Enrolled Onto a Randomized Phase 3 Clinical Trial: Data From the FIRE-3 Study. <i>Clinical Colorectal Cancer</i> , 2018 , 17, 215-222.e3	3.8	3
147	Polymorphism in the circadian clock pathway to predict outcome in patients (pts) with metastatic colorectal cancer (mCRC): Data from TRIBE and FIRE-3 phase III trials.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 3576-3576	2.2	1
146	Matrix metalloproteinase-related gene polymorphisms to predict efficacy of regorafenib in patients with metastatic colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 692-692	2.2	1
145	Microsatellite instability in colorectal cancer: overview of its clinical significance and novel perspectives. <i>Clinical Advances in Hematology and Oncology</i> , 2018 , 16, 735-745	0.6	40
144	Pharmacogenomics in colorectal cancer: current role in clinical practice and future perspectives. <i>Journal of Cancer Metastasis and Treatment</i> , 2018 , 4,	3.8	2
143	CXCL9, CXCL10, CXCL11/CXCR3 axis for immune activation - A target for novel cancer therapy. <i>Cancer Treatment Reviews</i> , 2018 , 63, 40-47	14.4	433
142	A Polymorphism within the Vitamin D Transporter Gene Predicts Outcome in Metastatic Colorectal Cancer Patients Treated with FOLFIRI/Bevacizumab or FOLFIRI/Cetuximab. <i>Clinical Cancer Research</i> , 2018 , 24, 784-793	12.9	14
141	Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair-Deficient/Microsatellite Instability-High Metastatic Colorectal Cancer. <i>Journal of Clinical Oncology</i> , 2018 , 36, 773-779	2.2	938
140	Management of Advanced Small Bowel Cancer. <i>Current Treatment Options in Oncology</i> , 2018 , 19, 69	5.4	8
139	Impact of primary tumour location on efficacy of bevacizumab plus chemotherapy in metastatic colorectal cancer. <i>British Journal of Cancer</i> , 2018 , 119, 1451-1455	8.7	14
138	What We Know About Stage II and III Colon Cancer: It's Still Not Enough. <i>Targeted Oncology</i> , 2017 , 12, 265-275	5	21
137	Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer: A Randomized Clinical Trial. <i>JAMA - Journal of the American Medical Association</i> , 2017 , 317, 2392-2401	27.4	434

136	Predictive value of TLR7 polymorphism for cetuximab-based chemotherapy in patients with metastatic colorectal cancer. <i>International Journal of Cancer</i> , 2017 , 141, 1222-1230	7.5	14
135	Single nucleotide polymorphisms in the IGF-IRS pathway are associated with outcome in mCRC patients enrolled in the FIRE-3 trial. <i>International Journal of Cancer</i> , 2017 , 141, 383-392	7.5	5
134	Autophagy-related polymorphisms predict hypertension in patients with metastatic colorectal cancer treated with FOLFIRI and bevacizumab: Results from TRIBE and FIRE-3 trials. <i>European Journal of Cancer</i> , 2017 , 77, 13-20	7.5	15
133	Potential role of polymorphisms in the transporter genes ENT1 and MATE1/OCT2 in predicting TAS-102 efficacy and toxicity in patients with refractory metastatic colorectal cancer. <i>European Journal of Cancer</i> , 2017 , 86, 197-206	7.5	16
132	Randomized study of etirinotecan pegol versus irinotecan as second-line treatment for metastatic colorectal cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2017 , 80, 1161-1169	3.5	2
131	Comparative molecular analyses of left-sided colon, right-sided colon, and rectal cancers. <i>Oncotarget</i> , 2017 , 8, 86356-86368	3.3	102
130	Colorectal cancer: epigenetic alterations and their clinical implications. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2017 , 1868, 439-448	11.2	35
129	Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study. <i>Lancet Oncology, The</i> , 2017 , 18, 1182-1191	21.7	1317
128	Tandem repeat variation near the HIC1 (hypermethylated in cancer 1) promoter predicts outcome of oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer. <i>Cancer</i> , 2017 , 123, 4506-4514	6.4	14
127	Understanding the role of primary tumour localisation in colorectal cancer treatment and outcomes. <i>European Journal of Cancer</i> , 2017 , 84, 69-80	7.5	136
126	Impact of genetic variations in the MAPK signaling pathway on outcome in metastatic colorectal cancer patients treated with first-line FOLFIRI and bevacizumab: data from FIRE-3 and TRIBE trials. <i>Annals of Oncology</i> , 2017 , 28, 2780-2785	10.3	19
125	Molecular Landscape and Treatment Options for Patients with Metastatic Colorectal Cancer. <i>Indian Journal of Surgical Oncology</i> , 2017 , 8, 580-590	0.7	2
124	Prognostic and Predictive Relevance of Primary Tumor Location in Patients With RAS Wild-Type Metastatic Colorectal Cancer: Retrospective Analyses of the CRYSTAL and FIRE-3 Trials. <i>JAMA Oncology</i> , 2017 , 3, 194-201	13.4	409
123	Combination of nivolumab (nivo) + ipilimumab (ipi) in the treatment of patients (pts) with deficient DNA mismatch repair (dMMR)/high microsatellite instability (MSI-H) metastatic colorectal cancer (mCRC): CheckMate 142 study.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 3531-3531	2.2	24
122	Randomized trial of irinotecan and cetuximab with or without vemurafenib in BRAF-mutant metastatic colorectal cancer (SWOG 1406).. <i>Journal of Clinical Oncology</i> , 2017 , 35, 520-520	2.2	85
121	Association of genetic variations in genes implicated in the axis with outcome in patients (pts) with metastatic colorectal cancer (mCRC) treated with cetuximab plus chemotherapy.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 3585-3585	2.2	1
120	Expression of Genes Involved in Vascular Morphogenesis and Maturation Predicts Efficacy of Bevacizumab-Based Chemotherapy in Patients Undergoing Liver Resection. <i>Molecular Cancer Therapeutics</i> , 2016 , 15, 2814-2821	6.1	6
119	A Phase II Biomarker-Embedded Study of Lapatinib plus Capecitabine as First-line Therapy in Patients with Advanced or Metastatic Gastric Cancer. <i>Molecular Cancer Therapeutics</i> , 2016 , 15, 2251-8	6.1	5

118	Molecular Pathways: Cachexia Signaling-A Targeted Approach to Cancer Treatment. <i>Clinical Cancer Research</i> , 2016 , 22, 3999-4004	12.9	57
117	Clinical Significance of TLR1 I602S Polymorphism for Patients with Metastatic Colorectal Cancer Treated with FOLFIRI plus Bevacizumab. <i>Molecular Cancer Therapeutics</i> , 2016 , 15, 1740-5	6.1	7
116	A novel antimetabolite: TAS-102 for metastatic colorectal cancer. <i>Expert Review of Clinical Pharmacology</i> , 2016 , 9, 355-65	3.8	7
115	TWIST1 Polymorphisms Predict Survival in Patients with Metastatic Colorectal Cancer Receiving First-Line Bevacizumab plus Oxaliplatin-Based Chemotherapy. <i>Molecular Cancer Therapeutics</i> , 2016 , 15, 1405-11	6.1	8
114	Colorectal cancer: Overcoming resistance to anti-EGFR therapy - where do we stand?. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2016 , 13, 258-9	24.2	10
113	Understanding the FOLFOXIRI-regimen to optimize treatment for metastatic colorectal cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2016 , 100, 117-26	7	1
112	Prognostic Impact of IL6 Genetic Variants in Patients with Metastatic Colorectal Cancer Treated with Bevacizumab-Based Chemotherapy. <i>Clinical Cancer Research</i> , 2016 , 22, 3218-26	12.9	16
111	Body Mass Index Is Prognostic in Metastatic Colorectal Cancer: Pooled Analysis of Patients From First-Line Clinical Trials in the ARCAD Database. <i>Journal of Clinical Oncology</i> , 2016 , 34, 144-50	2.2	76
110	Impact of primary (1 st) tumor location on overall survival (OS) and progression-free survival (PFS) in patients (pts) with metastatic colorectal cancer (mCRC): Analysis of CALGB/SWOG 80405 (Alliance).. <i>Journal of Clinical Oncology</i> , 2016 , 34, 3504-3504	2.2	193
109	Genetic variations associated with cancer cachexia pathways to predict survival in metastatic colorectal cancer (mCRC): Results from FIRE-3 and TRIBE.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 3590-3590	2.2	1
108	MAVERICC, a phase 2 study of mFOLFOX6-bevacizumab (BV) vs FOLFIRI-BV with biomarker stratification as first-line (1L) chemotherapy (CT) in patients (pts) with metastatic colorectal cancer (mCRC).. <i>Journal of Clinical Oncology</i> , 2016 , 34, 493-493	2.2	15
107	Impact of sex, age, and ethnicity/race on the survival of patients with rectal cancer in the United States from 1988 to 2012. <i>Oncotarget</i> , 2016 , 7, 53668-53678	3.3	16
106	CDX2 as a Prognostic Biomarker in Colon Cancer. <i>New England Journal of Medicine</i> , 2016 , 374, 2183	59.2	5
105	The safety of monoclonal antibodies for treatment of colorectal cancer. <i>Expert Opinion on Drug Safety</i> , 2016 , 15, 799-808	4.1	21
104	Novel therapeutics in metastatic colorectal cancer: molecular insights and pharmacogenomic implications. <i>Expert Review of Clinical Pharmacology</i> , 2016 , 9, 1091-108	3.8	8
103	Phase II Study of Olaparib (AZD-2281) After Standard Systemic Therapies for Disseminated Colorectal Cancer. <i>Oncologist</i> , 2016 , 21, 172-7	5.7	44
102	Association of variants in genes encoding for macrophage-related functions with clinical outcome in patients with locoregional gastric cancer. <i>Annals of Oncology</i> , 2015 , 26, 332-9	10.3	20
101	Primary tumor location as a prognostic factor in metastatic colorectal cancer. <i>Journal of the National Cancer Institute</i> , 2015 , 107,	9.7	298

100	Fluorouracil, leucovorin, and irinotecan plus cetuximab treatment and RAS mutations in colorectal cancer. <i>Journal of Clinical Oncology</i> , 2015 , 33, 692-700	2.2	515
99	Pharmacogenetic Analysis of INT 0144 Trial: Association of Polymorphisms with Survival and Toxicity in Rectal Cancer Patients Treated with 5-FU and Radiation. <i>Clinical Cancer Research</i> , 2015 , 21, 1583-90	12.9	8
98	Cytokeratin-20 and Survivin-Expressing Circulating Tumor Cells Predict Survival in Metastatic Colorectal Cancer Patients by a Combined Immunomagnetic qRT-PCR Approach. <i>Molecular Cancer Therapeutics</i> , 2015 , 14, 2401-8	6.1	21
97	Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial. <i>Lancet Oncology</i> , 2015 , 16, 937-48	21.7	240
96	The Molecular Taxonomy of Colorectal Cancer: What's New?. <i>Current Colorectal Cancer Reports</i> , 2015 , 11, 118-124	1	1
95	Randomized trial of TAS-102 for refractory metastatic colorectal cancer. <i>New England Journal of Medicine</i> , 2015 , 372, 1909-19	59.2	720
94	Variations in genes involved in dormancy associated with outcome in patients with resected colorectal liver metastases. <i>Annals of Oncology</i> , 2015 , 26, 1728-33	10.3	6
93	Molecular classification of gastric adenocarcinoma: translating new insights from the cancer genome atlas research network. <i>Current Treatment Options in Oncology</i> , 2015 , 16, 17	5.4	43
92	Genetic variants within obesity-related genes are associated with tumor recurrence in patients with stages II/III colon cancer. <i>Pharmacogenetics and Genomics</i> , 2015 , 25, 30-7	1.9	11
91	Pharmacogenomics of fluorouracil -based chemotherapy toxicity. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2015 , 11, 811-21	5.5	32
90	Polymorphisms in Genes Involved in EGFR Turnover Are Predictive for Cetuximab Efficacy in Colorectal Cancer. <i>Molecular Cancer Therapeutics</i> , 2015 , 14, 2374-81	6.1	3
89	Molecular Pathways: Hippo Signaling, a Critical Tumor Suppressor. <i>Clinical Cancer Research</i> , 2015 , 21, 5002-7	12.9	42
88	Predictive and prognostic markers in the treatment of metastatic colorectal cancer (mCRC): personalized medicine at work. <i>Hematology/Oncology Clinics of North America</i> , 2015 , 29, 43-60	3.1	24
87	TAS-102, a novel antitumor agent: a review of the mechanism of action. <i>Cancer Treatment Reviews</i> , 2015 , 41, 777-83	14.4	80
86	Genetic variations in angiopoietin and pericyte pathways and clinical outcome in patients with resected colorectal liver metastases. <i>Cancer</i> , 2015 , 121, 1898-905	6.4	9
85	Molecular subtypes and outcomes in regorafenib-treated patients with metastatic colorectal cancer (mCRC) enrolled in the CORRECT trial.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 3558-3558	2.2	15
84	LUME-Colon 1: A double-blind, randomized phase III study of nintedanib plus best supportive care (BSC) versus placebo plus BSC in patients with colorectal cancer (CRC) refractory to standard therapies.. <i>Journal of Clinical Oncology</i> , 2015 , 33, TPS3625-TPS3625	2.2	1
83	Standing the test of time: targeting thymidylate biosynthesis in cancer therapy. <i>Nature Reviews Clinical Oncology</i> , 2014 , 11, 282-98	19.4	236

82	Molecular pathways: turning proteasomal protein degradation into a unique treatment approach. <i>Clinical Cancer Research</i> , 2014 , 20, 3064-70	12.9	11
81	The potential of targeting Wnt/ β -catenin in colon cancer. <i>Expert Opinion on Therapeutic Targets</i> , 2014 , 18, 611-5	6.4	148
80	Polymorphisms in folate-metabolizing enzymes and response to 5-fluorouracil among patients with stage II or III rectal cancer (INT-0144; SWOG 9304). <i>Cancer</i> , 2014 , 120, 3329-3337	6.4	11
79	CXCR2 inhibition enhances sulindac-mediated suppression of colon cancer development. <i>International Journal of Cancer</i> , 2014 , 135, 232-7	7.5	11
78	Panitumumab : leading to better overall survival in metastatic colorectal cancer?. <i>Expert Opinion on Biological Therapy</i> , 2014 , 14, 535-48	5.4	1
77	Panitumumab safety for treating colorectal cancer. <i>Expert Opinion on Drug Safety</i> , 2014 , 13, 843-51	4.1	9
76	The kinase LMTK3 promotes invasion in breast cancer through GRB2-mediated induction of integrin α 5 β 1. <i>Science Signaling</i> , 2014 , 7, ra58	8.8	26
75	Plastin polymorphisms predict gender- and stage-specific colon cancer recurrence after adjuvant chemotherapy. <i>Molecular Cancer Therapeutics</i> , 2014 , 13, 528-39	6.1	27
74	ADAM17-dependent c-MET-STAT3 signaling mediates resistance to MEK inhibitors in KRAS mutant colorectal cancer. <i>Cell Reports</i> , 2014 , 7, 1940-55	10.6	74
73	Sustained inhibition of deacetylases is required for the antitumor activity of the histone deacetylase inhibitors panobinostat and vorinostat in models of colorectal cancer. <i>Investigational New Drugs</i> , 2013 , 31, 845-57	4.3	16
72	Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. <i>Lancet, The</i> , 2013 , 381, 303-12	4 ⁰	1783
71	Protein kinase inhibitors in metastatic colorectal cancer. Let's pick patients, tumors, and kinase inhibitors to piece the puzzle together!. <i>Expert Opinion on Pharmacotherapy</i> , 2013 , 14, 2203-20	4	4
70	Markers of response for the antiangiogenic agent bevacizumab. <i>Journal of Clinical Oncology</i> , 2013 , 31, 1219-30	2.2	272
69	Prognostic role of lemur tyrosine kinase-3 germline polymorphisms in adjuvant gastric cancer in Japan and the United States. <i>Molecular Cancer Therapeutics</i> , 2013 , 12, 2261-72	6.1	17
68	Prospective validation of candidate SNPs of VEGF/VEGFR pathway in metastatic colorectal cancer patients treated with first-line FOLFIRI plus bevacizumab. <i>PLoS ONE</i> , 2013 , 8, e66774	3.7	55
67	A phase I first-in-human study of PRI-724 in patients (pts) with advanced solid tumors.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 2501-2501	2.2	61
66	Analysis of plasma protein biomarkers from the CORRECT phase III study of regorafenib for metastatic colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 3514-3514	2.2	4
65	Selecting the best targeted agent in first-line treatment of unresectable liver metastases from colorectal cancer: does the bench have the answers?. <i>Journal of Hepato-Biliary-Pancreatic Sciences</i> , 2012 , 19, 528-35	2.8	2

64	Pancreatic cancer: medical management (novel chemotherapeutics). <i>Gastroenterology Clinics of North America</i> , 2012 , 41, 189-209	4.4	26
63	. <i>Current Colorectal Cancer Reports</i> , 2012 , 8, 263-271	1	1
62	Targeting IL-8 in colorectal cancer. <i>Expert Opinion on Therapeutic Targets</i> , 2012 , 16, 491-7	6.4	53
61	The CXCR2 antagonist, SCH-527123, shows antitumor activity and sensitizes cells to oxaliplatin in preclinical colon cancer models. <i>Molecular Cancer Therapeutics</i> , 2012 , 11, 1353-64	6.1	79
60	LMTK3 expression in breast cancer: association with tumor phenotype and clinical outcome. <i>Breast Cancer Research and Treatment</i> , 2012 , 132, 537-44	4.4	29
59	Influence of sex on the survival of patients with esophageal cancer. <i>Journal of Clinical Oncology</i> , 2012 , 30, 2265-72	2.2	85
58	Inhibition of dUTPase induces synthetic lethality with thymidylate synthase-targeted therapies in non-small cell lung cancer. <i>Molecular Cancer Therapeutics</i> , 2012 , 11, 616-28	6.1	40
57	A phase I study of veliparib in combination with metronomic cyclophosphamide in adults with refractory solid tumors and lymphomas. <i>Clinical Cancer Research</i> , 2012 , 18, 1726-34	12.9	160
56	LMTK3 polymorphism in patients with metastatic colon cancer.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 471-471	2.2	4
55	Kinome screening for regulators of the estrogen receptor identifies LMTK3 as a new therapeutic target in breast cancer. <i>Nature Medicine</i> , 2011 , 17, 715-9	50.5	101
54	Interleukin-8 is associated with proliferation, migration, angiogenesis and chemosensitivity in vitro and in vivo in colon cancer cell line models. <i>International Journal of Cancer</i> , 2011 , 128, 2038-49	7.5	306
53	Germline polymorphisms in genes involved in the CD44 signaling pathway are associated with clinical outcome in localized gastric adenocarcinoma. <i>International Journal of Cancer</i> , 2011 , 129, 1096-104	7.5	27
52	Pharmacogenetic angiogenesis profiling for first-line Bevacizumab plus oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer. <i>Clinical Cancer Research</i> , 2011 , 17, 5783-92	12.9	67
51	Gender-specific genomic profiling in metastatic colorectal cancer patients treated with 5-fluorouracil and oxaliplatin. <i>Pharmacogenomics</i> , 2011 , 12, 27-39	2.6	17
50	The dual EGFR/HER2 inhibitor lapatinib synergistically enhances the antitumor activity of the histone deacetylase inhibitor panobinostat in colorectal cancer models. <i>Cancer Research</i> , 2011 , 71, 3635-48	10.1	72
49	GRP78 promoter polymorphism rs391957 as potential predictor for clinical outcome in gastric and colorectal cancer patients. <i>Annals of Oncology</i> , 2011 , 22, 2431-2439	10.3	19
48	Common cancer stem cell gene variants predict colon cancer recurrence. <i>Clinical Cancer Research</i> , 2011 , 17, 6934-43	12.9	84
47	A let-7 microRNA-binding site polymorphism in 3'-untranslated region of KRAS gene predicts response in wild-type KRAS patients with metastatic colorectal cancer treated with cetuximab monotherapy. <i>Annals of Oncology</i> , 2011 , 22, 104-109	10.3	109

46	Survival of metastatic gastric cancer: Significance of age, sex and race/ethnicity. <i>Journal of Gastrointestinal Oncology</i> , 2011 , 2, 77-84	2.8	121
45	Germline polymorphisms in genes involved in the IGF1 pathway predict efficacy of cetuximab in wild-type KRAS mCRC patients. <i>Clinical Cancer Research</i> , 2010 , 16, 5591-602	12.9	38
44	A phase I/II trial of vorinostat in combination with 5-fluorouracil in patients with metastatic colorectal cancer who previously failed 5-FU-based chemotherapy. <i>Cancer Chemotherapy and Pharmacology</i> , 2010 , 65, 979-88	3.5	44
43	Using The Colon Cancer Multigene Recurrence Score to Determine Risk: Prognostic Milestone or a Step in the Right Direction?. <i>Current Colorectal Cancer Reports</i> , 2010 , 6, 183-192	1	
42	The colorectal cancer disease-specific transcriptome may facilitate the discovery of more biologically and clinically relevant information. <i>BMC Cancer</i> , 2010 , 10, 687	4.8	5
41	Gender disparities in metastatic colorectal cancer survival. <i>Clinical Cancer Research</i> , 2009 , 15, 6391-7	12.9	135
40	Histone deacetylase inhibitors suppress thymidylate synthase gene expression and synergize with the fluoropyrimidines in colon cancer cells. <i>International Journal of Cancer</i> , 2009 , 125, 463-73	7.5	61
39	DNA microarray profiling of genes differentially regulated by the histone deacetylase inhibitors vorinostat and LBH589 in colon cancer cell lines. <i>BMC Medical Genomics</i> , 2009 , 2, 67	3.7	66
38	Pharmacogenomics and -genetics in colorectal cancer. <i>Advanced Drug Delivery Reviews</i> , 2009 , 61, 375-80	18.5	14
37	First-line combination treatment of colorectal cancer with hepatic metastases: choosing a targeted agent. <i>Cancer Treatment Reviews</i> , 2008 , 34 Suppl 2, S3-7	14.4	73
36	EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. <i>Journal of Clinical Oncology</i> , 2008 , 26, 2311-9	2.2	757
35	Polymorphisms and clinical outcome in recurrent ovarian cancer treated with cyclophosphamide and bevacizumab. <i>Clinical Cancer Research</i> , 2008 , 14, 7554-63	12.9	163
34	Clinical determinants of response to irinotecan-based therapy derived from cell line models. <i>Clinical Cancer Research</i> , 2008 , 14, 6647-55	12.9	18
33	Thymidylate synthase haplotype is associated with tumor recurrence in stage II and stage III colon cancer. <i>Pharmacogenetics and Genomics</i> , 2008 , 18, 161-8	1.9	48
32	Can we predict the response to epidermal growth factor receptor targeted therapy?. <i>Targeted Oncology</i> , 2008 , 3, 87-99	5	1
31	Individualization of therapy based on clinical and molecular parameters. <i>Current Colorectal Cancer Reports</i> , 2008 , 4, 193-200	1	1
30	EGFR, HER2 and VEGF pathways: validated targets for cancer treatment. <i>Drugs</i> , 2007 , 67, 2045-75	12.1	97
29	Serum lactate dehydrogenase levels and glycolysis significantly correlate with tumor VEGFA and VEGFR expression in metastatic CRC patients. <i>Pharmacogenomics</i> , 2007 , 8, 1705-13	2.6	50

28	Management and preparedness for infusion and hypersensitivity reactions. <i>Oncologist</i> , 2007 , 12, 601-9	5.7	335
27	The continuum of care: a paradigm for the management of metastatic colorectal cancer. <i>Oncologist</i> , 2007 , 12, 38-50	5.7	190
26	Association of methylenetetrahydrofolate reductase gene polymorphisms and sex-specific survival in patients with metastatic colon cancer. <i>Journal of Clinical Oncology</i> , 2007 , 25, 3726-31	2.2	56
25	FCGR2A and FCGR3A polymorphisms associated with clinical outcome of epidermal growth factor receptor expressing metastatic colorectal cancer patients treated with single-agent cetuximab. <i>Journal of Clinical Oncology</i> , 2007 , 25, 3712-8	2.2	407
24	Predictive and prognostic markers in colorectal cancer. <i>Gastrointestinal Cancer Research: GCR</i> , 2007 , 1, 237-46		9
23	Molecular determinants of irinotecan efficacy. <i>International Journal of Cancer</i> , 2006 , 119, 2435-42	7.5	50
22	Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines. <i>Journal of Clinical Oncology</i> , 2006 , 24, 4914-21 ²	2.2	450
21	Novel approaches to treatment of advanced colorectal cancer with anti-EGFR monoclonal antibodies. <i>Annals of Medicine</i> , 2006 , 38, 545-51	1.5	47
20	Genomic profiling associated with recurrence in patients with rectal cancer treated with chemoradiation. <i>Pharmacogenomics</i> , 2006 , 7, 67-88	2.6	51
19	Determinants of chemosensitivity in gastric cancer. <i>Current Opinion in Pharmacology</i> , 2006 , 6, 337-44	5.1	39
18	Gene expression in tumor-adjacent normal tissue is associated with recurrence in patients with rectal cancer treated with adjuvant chemoradiation. <i>Pharmacogenetics and Genomics</i> , 2006 , 16, 555-63	1.9	18
17	Cyclin D1 and epidermal growth factor polymorphisms associated with survival in patients with advanced colorectal cancer treated with Cetuximab. <i>Pharmacogenetics and Genomics</i> , 2006 , 16, 475-83	1.9	90
16	Pharmacogenomics and colorectal cancer. <i>Advances in Experimental Medicine and Biology</i> , 2006 , 587, 211-31	3.6	23
15	Gene polymorphisms of epidermal growth factor receptor and its downstream effector, interleukin-8, predict oxaliplatin efficacy in patients with advanced colorectal cancer. <i>Clinical Colorectal Cancer</i> , 2005 , 5, 124-31	3.8	54
14	Epidermal Growth Factor Receptor as a Target for Chemotherapy. <i>Clinical Colorectal Cancer</i> , 2005 , 5, S19-S27	3.8	47
13	Molecular determinants of cetuximab efficacy. <i>Journal of Clinical Oncology</i> , 2005 , 23, 3536-44	2.2	205
12	Antiangiogenic agents in cancer therapy. <i>Oncology</i> , 2005 , 19, 17-25	1.8	11
11	Capecitabine: the new generation of fluoropyrimidines in colorectal cancer. <i>Expert Review of Anticancer Therapy</i> , 2004 , 4, 947-55	3.5	4

10	Integration of novel agents in the treatment of colorectal cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2004 , 54 Suppl 1, S32-9	3.5	18
9	The role of proteasome inhibitors in solid tumors. <i>Annals of Medicine</i> , 2004 , 36, 296-303	1.5	27
8	Pharmacogenetic aspects in treatment of colorectal cancer--an update. <i>Pharmacogenomics</i> , 2003 , 4, 767-778	2.0	4
7	Pharmakogenetik in kolorektalen Karzinomen. <i>Onkologe</i> , 2003 , 9, 860-864	0.1	
6	Tailoring chemotherapy in advanced colorectal cancer. <i>Current Opinion in Pharmacology</i> , 2003 , 3, 378-85	5.1	23
5	Implications of genetic testing in the management of colorectal cancer. <i>Molecular Diagnosis and Therapy</i> , 2003 , 3, 73-88		9
4	A novel single nucleotide polymorphism within the 5' tandem repeat polymorphism of the thymidylate synthase gene abolishes USF-1 binding and alters transcriptional activity. <i>Cancer Research</i> , 2003 , 63, 2898-904	10.1	252
3	Thymidylate synthase gene polymorphism predicts response to capecitabine in advanced colorectal cancer. <i>International Journal of Colorectal Disease</i> , 2002 , 17, 46-9	3	84
2	Association between glutathione S-transferase P1, T1, and M1 genetic polymorphism and survival of patients with metastatic colorectal cancer. <i>Journal of the National Cancer Institute</i> , 2002 , 94, 936-42	9.7	289
1	ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy. <i>Journal of Clinical Oncology</i> , 2001 , 19, 4298-304	2.2	565